News Releases

Filter News Releases by year:
2022 | 2021 | 2020 | 2019 | 2018
Showing results filtered by:
Clear All
Vaccine Research Center (VRC)
31 Results

May 2022

Vaccine for Rare but Deadly Mosquito-Borne Viruses Shows Promise in Clinical Trial

May 12, 2022

A vaccine for eastern equine encephalitis virus (EEEV), western equine encephalitis virus (WEEV), and Venezuelan equine encephalitis virus (VEEV) was found to be safe, well-tolerated and induced a neutralizing antibody response in adult volunteers, according to newly published results from a Phase 1 clinical trial. The vaccine candidate was developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC), part of the National Institutes of Health.

a black mosquito with white stripes bites human skin

February 2022

Leadership Transition at the NIAID Vaccine Research Center

February 16, 2022

I extend my heartfelt gratitude and deepest respect to John R. Mascola, M.D., as he announces his retirement as Director of the Dale and Betty Bumpers Vaccine Research Center at the National Institute of Allergy and Infectious Diseases. Dr. Mascola will leave NIAID at the end of March.

December 2021

Experimental mRNA HIV Vaccine Safe, Shows Promise in Animals

December 09, 2021

An experimental HIV vaccine based on mRNA—the same platform technology used in two highly effective COVID-19 vaccines—shows promise in mice and non-human primates, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Their results, published in Nature Medicine, show that the novel vaccine was safe and prompted desired antibody and cellular immune responses against an HIV-like virus.

HIV infected H9 T cell

August 2021

Monoclonal Antibody Prevents Malaria in Small NIH Trial

August 11, 2021

One dose of a new monoclonal antibody discovered and developed at the National Institutes of Health safely prevented malaria for up to nine months in people who were exposed to the malaria parasite. The small, carefully monitored clinical trial is the first to demonstrate that a monoclonal antibody can prevent malaria in people. The trial was sponsored and conducted by scientists from the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, and was funded by NIAID.

Malaria parasite connecting to human red blood cell

June 2021

NIH Launches Clinical Trial of Universal Influenza Vaccine Candidate

June 01, 2021

A first-in-human, Phase 1 trial assessing the safety and immunogenicity of an investigational nanoparticle influenza vaccine designed to provide long-lasting protection against multiple flu virus strains has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland. Healthy participants 18 to 50 years old will receive either a licensed seasonal influenza vaccine or the experimental vaccine, FluMos-v1.

computer-generated image of nanoparticle influenza vaccine

February 2021

NIH Experts Discuss SARS-CoV-2 Viral Variants

February 12, 2021

The rise of several significant variants of SARS-CoV-2 has attracted the attention of health and science experts worldwide, NIH reports.

January 2021

Media Availability—NIH Officials Highlight COVID-19 Vaccine Facts, Unknowns for Healthcare Providers

January 18, 2021

NIAID Director urges healthcare providers to be able to explain the latest data supporting the safety and efficacy of vaccines for COVID-19.

July 2020

Experimental COVID-19 Vaccine Protects Upper and Lower Airways in Nonhuman Primates

July 28, 2020

NIAID-led study shows that experimental COVID-19 mRNA vaccine protects upper and lower airways in nonhuman primates.

Colorized scanning electron micrograph of a cell (blue) heavily infected with SARS-CoV-2 virus particles (red), isolated from a patient sample.

Experimental COVID-19 Vaccine Safe, Generates Immune Response

July 14, 2020

A NIAID-sponsored experimental COVID-19 vaccine was generally well tolerated and prompted neutralizing antibody activity in health adults.

Colorized scanning electron micrograph of an apoptotic cell (green) heavily infected with SARS-COV-2 virus particles (purple)

March 2020

Drug-Delivery Technology Leads to Sustained HIV Antibody Production in NIH Study

March 09, 2020

An NIH study finds that a new drug-delivery technology leads to sustained HIV antibody production.

January 2020

First Human Trial of Monoclonal Antibody to Prevent Malaria Opens

January 27, 2020

A Phase 1 clinical trial testing the safety and effectiveness of a monoclonal antibody (mAb) against malaria has begun enrolling healthy adult volunteers at the National Institutes of Health Clinical Center in Bethesda, Maryland. The trial, sponsored by NIH’s National Institute of Allergy and Infectious Diseases (NIAID), is the first to test mAb CIS43LS in humans. It aims to enroll up to 73 volunteers aged 18 through 50 years old who have never had malaria.

Volunteer received experimental monoclonal antibody against malaria

Changed Route of Immunization Dramatically Improves Efficacy of TB Vaccine

January 01, 2020

Tuberculosis (TB), an ancient disease, is the leading infectious cause of death globally, yet the world’s only licensed TB vaccine, Bacille Calmette-Guerin (BCG), was developed a century ago. Given to infants via a needle placed just under the skin, BCG protects babies from a form of the disease called disseminated TB but is far less effective at preventing pulmonary TB, the major cause of illness and deaths, in teens or adults. 

Images of animal lungs showing substantial areas of TB infection (top row) or very little or no infection (bottom row)

December 2019

NIH-Developed Zika Vaccine Improves Fetal Outcomes in Animal Model

December 19, 2019

A new study finds that an NIH-developed Zika vaccine improves fetal outcomes in an animal model.

vial of investigational DNA Zika vaccine

August 2019

Experimental Respiratory Syncytial Virus Vaccine Prompts Antibody Surge

August 01, 2019

Information about how NIAID supports the research of HIV treatment in infants and children.

Colorized scanning electron micrograph of human respiratory syncytial virus (RSV) virions (blue) and labeled with anti-RSV F protein/gold antibodies (yellow) shedding from the surface of human lung epithelial cells.

April 2019

NIH Begins First-in-Human Trial of a Universal Influenza Vaccine Candidate

April 03, 2019

The first clinical trial of an innovative universal influenza vaccine candidate is examining the vaccine’s safety and tolerability as well as its ability to induce an immune response in healthy volunteers. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, developed the experimental vaccine, known as H1ssF_3928. 

volunteer receives an experimental universal influenza vaccine

January 2019

Investigational Monoclonal Antibody to Treat Ebola Is Safe in Adults

January 24, 2019

The investigational Ebola treatment mAb114 is safe, well-tolerated, and easy to administer, according to findings from an early-stage clinical trial published in The Lancet. Eighteen healthy adults received the monoclonal antibody as part of a Phase 1 clinical trial that began in May 2018 at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. The National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC), part of NIH, developed the investigational treatment and conducted and sponsored the clinical trial.

A healthy volunteer receives an intravenous infusion of mAb114—an experimental treatment for Ebola virus disease

June 2018

HIV Vaccine Elicits Antibodies in Animals that Neutralize Dozens of HIV Strains

June 04, 2018

An experimental vaccine regimen based on the structure of a vulnerable site on HIV elicited antibodies in mice, guinea pigs and monkeys that neutralize dozens of HIV strains from around the world. The findings were reported today in the journal Nature Medicine by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and their colleagues. 

Protein structure diagram illustrates the location of the fusion peptide epitope on the HIV spike, which projects out of the viral membrane. The diagram also shows how a broadly neutralizing antibody binds to the fusion peptide.

March 2018

NIH Scientists Say Advanced Vaccines Could Limit Future Outbreaks

March 22, 2018

NIAID reports novel vaccine technologies are critical to improving public health response to infectious disease threats that emerge and re-emerge.

Newly Described Human Antibody Prevents Malaria in Mice

March 19, 2018

Scientists have discovered a human antibody that protected mice from infection with the deadliest malaria parasite, Plasmodium falciparum. The research findings provide the basis for future testing in humans to determine if the antibody can provide short-term protection against malaria, and also may aid in vaccine design. Investigators at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, led the research with colleagues at the Fred Hutchinson Cancer Research Center in Seattle.

Malaria sporozoites, the infectious form of the malaria parasite.

December 2017

Gene-Based Zika Vaccine is Safe and Immunogenic in Healthy Adults

December 04, 2017

Results from two Phase 1 clinical trials show an experimental Zika vaccine developed by government scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is safe and induces an immune response in healthy adults. The findings will be published on Dec. 4 in The Lancet. NIAID is currently leading an international effort to evaluate the investigational vaccine in a Phase 2/2b safety and efficacy trial.

A Zika virus researcher pipets samples at the NIAID Vaccine Research Center lab.

NIH Statement on World AIDS Day 2017

December 01, 2017

Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases
Maureen M. Goodenow, Ph.D., Director, Office of AIDS Research

September 2017

Three-in-One Antibody Protects Monkeys from HIV-Like Virus

September 20, 2017

A three-pronged antibody made in the laboratory protected monkeys from infection with two strains of SHIV, a monkey form of HIV, better than individual natural antibodies from which the engineered antibody is derived, researchers report in Science today.

Diagram of the “three-in-one” HIV antibody. Each segment binds to a different critical site on the virus. 

March 2017

Phase 2 Zika Vaccine Trial Begins in U.S., Central and South America

March 31, 2017

Phase 2 of an NIH Zika vaccine clinical trial begins in the United States, Central and South America.

Monkeys Suppress HIV-Like Virus for Extended Period after Dual-Antibody Treatment

March 13, 2017

Giving monkeys two powerful anti-HIV antibodies immediately after infection with an HIV-like virus enabled the immune systems of some of the animals to control the virus long after the antibodies were gone, scientists at the National Institutes of Health and The Rockefeller University have found.  

Protein-structure model shows how the broadly neutralizing antibodies 10-1074 and 3BNC117 each bind to a different site on the SHIV spike, helping prevent the virus from escaping the antibodies.

Investigational Vaccine Protects Cattle from Respiratory Syncytial Virus

March 10, 2017

A novel vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, protected cattle from respiratory syncytial virus (RSV) infection, according to research published online in npj Vaccines on March 8. The research was conducted by a team of experts at NIAID, the Pirbright Institute based in the United Kingdom, and the Institute for Research in Biomedicine in Switzerland.